acute myeloid leukemia

[Annals of Hematology] In this first clinical, phase I, dose-escalation and -expansion study, scientists evaluated CC-90002 in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

[Molecular Cancer] CRISPR/Cas9 approaches were used to generate stem cell leukemia/lymphoma syndrome cells null for Interleukin receptor associated kinase 1 and interferon gamma which were introduced into syngeneic hosts through tail vein injection.

[Clinical Cancer Research] Scientists investigated the recommended dose for expansion of siremadlin, a p53-MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers.

[Leukemia] Utilizing a Flt3-ITD knock-in, Dnmt3a haploinsufficient mouse model, researchers demonstrated that Gab2 was essential for the development of Flt3-ITD driven acute myeloid leukemia in vivo, asGab2 deficient mice displayed prolonged survival, presented with attenuated liver and spleen pathology and reduced blast counts.

[Molecular Partners AG] Molecular Partners AG announced a research collaboration with University of Bern, to advance the development of the company’s wholly owned acute myeloid leukemia candidate, MP0533, into the clinic.

[Cancer Discovery] To identify key epigenetic regulators of acute myeloid leukemia (AML) cell fate, researchers performed a differentiation-focused CRISPR screen in AML cells, which identified the histone acetyltransferase KAT6A as a novel regulator of myeloid differentiation that drives critical leukemogenic gene expression programs.